Related references
Note: Only part of the references are listed.Real-World Effectiveness of Antipsychotic Treatments in a Nationwide Cohort of 29 823 Patients With Schizophrenia
Jari Tiihonen et al.
JAMA PSYCHIATRY (2017)
Mortality and Self-Harm in Association With Clozapine in Treatment-Resistant Schizophrenia
Theresa Wimberley et al.
AMERICAN JOURNAL OF PSYCHIATRY (2017)
The impact of clozapine on hospital use: a systematic review and meta-analysis
R. Land et al.
ACTA PSYCHIATRICA SCANDINAVICA (2017)
Factors associated with changes in hospitalisation in patients prescribed clozapine
Siobhan H. Gee et al.
JOURNAL OF PSYCHOPHARMACOLOGY (2016)
Cohort profile of the South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLaM BRC) Case Register: current status and recent enhancement of an Electronic Mental Health Record-derived data resource
Gayan Perera et al.
BMJ OPEN (2016)
Effectiveness and safety of clozapine in elderly patients with chronic resistant schizophrenia
Shani Pridan et al.
INTERNATIONAL PSYCHOGERIATRICS (2015)
The Effect of Clozapine on Premature Mortality: An Assessment of Clinical Monitoring and Other Potential Confounders
Richard D. Hayes et al.
SCHIZOPHRENIA BULLETIN (2015)
Clozapine's Role in the Treatment of First-Episode Schizophrenia
Gary Remington et al.
AMERICAN JOURNAL OF PSYCHIATRY (2013)
Comorbidities and Mortality in Persons With Schizophrenia: A Swedish National Cohort Study
Casey Crump et al.
AMERICAN JOURNAL OF PSYCHIATRY (2013)
Getting More Out of Biomedical Documents with GATE's Full Lifecycle Open Source Text Analytics
Hamish Cunningham et al.
PLOS COMPUTATIONAL BIOLOGY (2013)
Real-world effectiveness of clozapine in patients with bipolar disorder: results from a 2-year mirror-image study
Jimmi Nielsen et al.
BIPOLAR DISORDERS (2012)
Adherence to treatment guidelines in clinical practice: study of antipsychotic treatment prior to clozapine initiation
Oliver D. Howes et al.
BRITISH JOURNAL OF PSYCHIATRY (2012)
Antipsychotic monotherapy and adjuvant psychotropic therapies in schizophrenia patients: effect on time to readmission
Avi Valevski et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2012)
Life Expectancy at Birth for People with Serious Mental Illness and Other Major Disorders from a Secondary Mental Health Care Case Register in London
Chin-Kuo Chang et al.
PLOS ONE (2011)
All-cause mortality among people with serious mental illness (SMI), substance use disorders, and depressive disorders in southeast London: a cohort study
Chin-Kuo Chang et al.
BMC PSYCHIATRY (2010)
Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
S. M. Stahl et al.
ACTA PSYCHIATRICA SCANDINAVICA (2009)
Atypical Antipsychotic Drugs and the Risk of Sudden Cardiac Death
Wayne A. Ray et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Using Patient-Reported Outcomes in Schizophrenia: The Scottish Schizophrenia Outcomes Study
Robert Hunter et al.
PSYCHIATRIC SERVICES (2009)
Clozapine and high-dose olanzapine in refractory early-onset schizophrenia: A 12-week randomized and double-blind comparison
Sanjiv Kumra et al.
BIOLOGICAL PSYCHIATRY (2008)
Rehospitalization rates of patients with schizophrenia discharged on haloperidol, risperidone or clozapine
Ana Paula Werneck de Castro et al.
REVISTA BRASILEIRA DE PSIQUIATRIA (2007)
Reduction in hospital stay of chronic schizophrenic patients after long-term clozapine treatment
YM Ahn et al.
INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2005)
Drug therapy: Drug-induced prolongation of the QT interval
DM Roden
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Share Paper
